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Summary.-It has been shown that lymphocytes isolated from the peripheral blood
of patients with chronic lymphocytic leukaemia do not modify the mustard group
of chlorambucil, as has been demonstrated previously in Yoshida ascites cells.
However, lymphocytes from patients with an unsatisfactory clinical course or poor
response to treatment were able to modify the aromatic region of the drug molecule;
little change occurred in the aromatic absorption of intracellular chlorambucil in
patients who responded to treatment. This simple test may provide a rapid assess-
ment of a patient's potential response to chemotherapy.
]DIFFERENCES in the utilization of
chlorambucil following its uptake by cells
in vitro have been demonstrated using
an experimental animal tumour system
(Harrap and Hill, 1970): cells of a drug-
resistant strain of the Yoshida ascites
sarcoma were capable of hydrolysing the
chloroethyl groups and modifying the
aromatic ring ofthe drug more extensively
than drug-sensitive cells. These 2 effects
led to the maintenance of a higher level
of unmodified drug in sensitive cells com-
pared with resistant cells. These studies
have now been extended to lymphocytes
isolated from the peripheral blood of
patients with chronic lymphocytic leuk-
aemia; if chlorambucil were metabolized
similarly in lymphocytes, this mechanism
might account in part for the failure of
such patients to respond to treatment.
MATERIALS AND METHODS
Chlorambucil (Leukeran) (ClCH2CH2)2
N.C6H4(CH2)3COOH was synthesized in
the Chester Beatty Research Institute. Poly-
brene (hexadimethrine bromide) was obtained
* The following abbreviations will be used
tetracetic acid, disodium salt; PBS phosphate
CLL-chronic lymphocytic leukaemia.
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from Abbott Laboratories Ltd., Queen-
borough, Kent. Other chemicals were pur-
chased from Hopkin and Williams Ltd., or
B.D.H. Ltd., AnalaR grades being used
where available. Siliconized glassware was
used throughout. A total of 20 ml of blood
was obtained from each of 14 patients by
cubital venepuncture and collected into
disodium EDTA* (10%).
Metabolic studies.-Blood cells were sedi-
mented at 350 g (40) for 10 min, and platelets
removed from the supernatant by centri-
fuging at 1500 g (4°) for 10 min. The
platelet-impoverished plasma was recom-
bined with the initial cell pellet, and 0 4 ml
of 1% polybrene added to neutralize the
anticoagulant action ofEDTA. The mixture
was inverted x 10, left to stand for 20 min
at room temperature, and then centrifuged
for 5 min at 15 g (40). The cell count in a
measured volume of the lymphocyte-rich
supernatant was determined in a modified
Fuchs - Rosenthal haemocytometer. The
lymphocytes were removed from suspension
by centrifugation, washed twice with 0-1%
EDTA (40), and finally resuspended in PBS
containing 0-1% w/v EDTA to a concen-
tration of 107 cells/ml.
Chlorambucil was dissolved in 1 vol of
throughout this paper: EDTA-ethylene diamine
buffered saline; PPG phosphate propylene glycol;BRIDGET T. HILL AND K. R. HARRAP
20 w/v HCl in ethanol and diluted with
9 vol of PPG solution to give a final concen-
tration of 5-4 mg/ml. (PPG was prepared
by dissolving 20 g of dipotassium hydrogen
phosphate and 450 ml of propylene glycol
in water and diluting to a final volume of
1 1.) Cell suspensions were prepared in
triplicate: 1 ml of chlorambucil solution was
added to 11 ml of cell suspension (final drug
concentration = 450 jig/ml). Control cell
suspensions received 1 ml of solvent only.
A further control consisted of 11 ml of
saspension medium and 1 ml of drug. The
samples were incubated in a metabolic
shaker (Gallenkamp) at 37°.
P_A_
Drug uptake was followed by with-
drawing 2 ml aliquots of cell suspension at
measured time intervals after drug addition.
An ethanolic cell extract was prepared as
described previously (Harrap and Hill, 1970).
The " total " drug content of these extracts
was determined by E258 measurements
using a chlorambucil standard curve pre-
pared under the same experimental condi-
tions; this provided an estimate of chloram-
bucil moieties containing an intact benzene
ring. The proportion of drug containing
functional mustard groups, " active " drug,
was determined by a modification of the
colorimetric procedure of Epstein, Rosenthal
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FiC. 2.- Drug levels in lymphocytes (measured by u.v. absorption at El58) after exposure in vitro to
chlorambucil
* 0 Chlorambucil in aqueous medium.
A......A Class I patients.
E _ }Class II patients.
Each point represents the mean of 4 determinations. The overall scatter about any point > 10%.
and Ess (1955) by reference to a standard
curve prepared under the same experimental
conditions. 2 ml of 2% w/v p-nitrobenzyl
pyridine in ethylene glycol were added to
1 ml of the ethanol extract and the mixture
was heated in a stoppered tube at 950 for
10 min. After cooling in ice, 2 ml of 50%0
w/v triethylamine solution in acetone was
added, the contents mixed thoroughly and
El65 measured within 2 min.
RESULTS
The rate of uptake of chlorambucil
by lymphocytes, and its subsequent hydro-
lysis, is shown in cells isolated from the
blood of several patients in Fig. 1; these
data are compared with the hydrolysis
rate of chlorambucil in aqueous medium.
Uptake occurs rapidly (within 5 min),
and the rate of hydrolysis is comparable
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with that in the " cell-free " control.
Essentially the same results were ob-
tained with cells from all 14 patients.
Fig. 2 shows that the benzenoid
component of the drug remained un-
modified in aqueous solution, and in the
cells from some patients (Class I). How-
ever, a second group of patients (Class II)
was distinguished by a progressive
decrease in the aromatic absorption of
intracellular drug. The accumulated data
are listed in Table I, together with
clinical details of all the patients studied.
DISCUSSION
The data reported here may be com-
pared with those of a previous study on
drug-sensitive and -resistant strains of
the Yoshida ascites sarcoma (Harrap and
Hill, 1970). The latter work indicated
that the chlorambucil molecule was modi-
fied in the mustard group, and also in
the benzene ring, by both cell types.
However, these 2 reactions were consider-
ably more extensive in the drug-resistant
cell strain. In the present work, the
mustard group of chlorambucil remained
unmodified by CLL lymphocytes. It was
also notable that these cells took up only
approximately 10% of that amount of
drug accumulated by Yoshida ascites
cells (for comparable cell and drug
concentrations).
In those patients who responded to
TABLE I.-Relationship between Intracellular Stability of Chlorambucil (as Measured
by its u.v. Absorption) and Clinical Response of CLL Patients to Treatment
Duration
of disease
Name Sex Age (years)
Lymphocyte count
per mm3
Pre- Post-
Drug used treatment treatment
CLAS
D.G. . F . 82 . 4 . Chlorambucil
K.R. . F . 69 . 2 . Chlorambucil
A.M. . M . 68 . 2
R.P. . M . 51 . 8
G.S. . M . 63 . 1
. Chlorambucil
Cyclo-
phosphamide
. Chlorambucil
J.H. . M . 69 . 3 . Chlorambucil
T.M. . F . 60 . 11 . Chlorambucil
* See also CLASS II
;s I
90000 6000
500000 7000
3 months later-
controlled at 7000
115000 13000
*46000 2900
250000 10000
*6 months later-
controlled at 10000
75000 6500
420000 3100
Response
to
treatment
Good
Good
Good
Good
Good
Good
Good
Good
Good
R.P. . M . 53 . 10
L.R. . F . 67 . 11
A.A. . M . 58 . 2
I.F. . M . 69 . 25
V.P. . F . 76 . 5
P.S. . M . 60 . >7
CLASS II
. Chlorambucil . 80000
. Cyclo- . 100000
phosphamide
. Chlorambucil . 577000
Chlorambucil
and cyclo-
phosphamide
G.S. . M . 66 . 4 . Chlorambucil
T.H. . M . 60 . >6
E.D. . F . 72 . >5
6 months
198000
No treatme
No treatme
75000
80000 . Poor
100000 . Poor
385000 Poor
3later
114000 . Poor
fnt given.
ynt given.
60000 Poor
3 years after initial
sample*
45000 4000
. Cyclo- . 4500
phosphamide
. Cyclo- . 3900
phosphamide
18000
Good
Poor
6360 . Poor
% aromatic
absorption
remaining
after 2 hours'
incubation
at 370 C
93
90
98
101
94
100
97
88
99
56
65
65
61
51
68
70
63
54
66
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treatmnent (Class I), little change occurred
in the aromatic absorption of intracellular
chlorambucil. On the other hand, when
the aromatic structure of the drug was
altered, in the in vitro assay, this could
be correlated with an unsatisfactory
clinical course or poor response to treat-
ment (Class II).
It should be noted that lymphocytes
from R.P., when first tested, failed to
degrade chlorambucil and at this time
the patient was responding to treatment.
When examined one year later lympho-
cytes from this patient did degrade the
drug and treatment then proved clinically
ineffective. In the case of G.S., in
vitro testing on 2 occasions in 1968
suggested that this patient would be
sensitive to chlorambucil, and this proved
to be the case clinically. However, sub-
sequent tests 3 years later indicated that
this patient's lymphocytes were now
degrading the drug though G.S. continued
to respond to treatment. Although this
behaviour represents the single exception
to the classification presented above,
G.S. will be followed up on this in vitro
screen in the event that he may subse-
quently develop resistance to treatment.
This simple test procedure may pro-
vide a rapid means of assessing a patient's
potential response to chemotherapy. Re-
cently other workers have proposed an
in vitro assay system to detect the
sensitivity of CLL lymphocytes to chlor-
ambucil (Lawler, Lele and Pentycross,
1971). This procedure is based on the
survival of cells cultured continuously in
the presence of the drug. Its disad-
vantage is the greater time required (5
days) for assessment of response. The
present method provides a result in a
few hours.
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